CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [Figure presented]

on behalf of the CheckMate 025 investigators

Research output: Contribution to journalArticlepeer-review

171 Scopus citations

Fingerprint

Dive into the research topics of 'CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma [Figure presented]'. Together they form a unique fingerprint.

Medicine & Life Sciences